Nuveen Asset Management LLC Grows Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

Nuveen Asset Management LLC lifted its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 38.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 585,839 shares of the company’s stock after buying an additional 162,886 shares during the quarter. Nuveen Asset Management LLC owned about 0.28% of Cellebrite DI worth $12,906,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in CLBT. Gen Wealth Partners Inc bought a new stake in Cellebrite DI during the 4th quarter worth approximately $85,000. NewEdge Advisors LLC increased its stake in shares of Cellebrite DI by 600.7% in the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company’s stock worth $86,000 after purchasing an additional 3,352 shares in the last quarter. R Squared Ltd bought a new stake in shares of Cellebrite DI during the 4th quarter valued at $100,000. Polen Capital Management LLC purchased a new position in shares of Cellebrite DI during the 4th quarter valued at $222,000. Finally, Victory Capital Management Inc. bought a new position in Cellebrite DI in the 4th quarter worth $234,000. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI Trading Up 3.0%

Shares of Cellebrite DI stock opened at $17.21 on Tuesday. The firm has a market cap of $4.12 billion, a PE ratio of -12.38, a PEG ratio of 4.27 and a beta of 1.44. The stock has a 50 day moving average of $18.88 and a 200 day moving average of $20.19. Cellebrite DI Ltd. has a 12 month low of $10.25 and a 12 month high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last posted its earnings results on Wednesday, May 14th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.01. Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. The firm had revenue of $107.55 million during the quarter, compared to the consensus estimate of $109.36 million. During the same period in the prior year, the company earned $0.08 EPS. The company’s quarterly revenue was up 20.0% compared to the same quarter last year. As a group, equities research analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CLBT has been the subject of a number of analyst reports. JPMorgan Chase & Co. cut their price target on Cellebrite DI from $29.00 to $25.00 and set an “overweight” rating for the company in a research note on Monday, May 12th. Needham & Company LLC cut their target price on Cellebrite DI from $28.00 to $24.00 and set a “buy” rating for the company in a research report on Wednesday, May 14th. Finally, Lake Street Capital boosted their price target on Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $22.43.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.